OPEN

SUBJECT AREAS:
INFECTIOUS DISEASES
VIRAL GENETICS

Received
7 April 2014

Accepted
12 August 2014

Published
17 October 2014

Correspondence and
requests for materials
should be addressed to
J.C. (jcasseb10@
gmail.com) or K.G.
(karengaester@usp.br)

Human papillomavirus infection in oral fluids of HIV-1-positive men: prevalence and risk factors

Karen Gaester^{1,2}, Luiz A. M. Fonseca³, Olinda Luiz³, Tatiane Assone^{1,2}, Adriele Souza Fontes^{1,2}, Fernando Costa^{1,2}, Alberto J. S. Duarte^{1,2} & Jorge Casseb^{1,2}

¹Laboratory of Dermatology and Immunodeficiencies, Department of Dermatology, University of São Paulo Medical School, Brazil, ²Institute of Tropical Medicine of São Paulo, São Paulo, SP, Brazil, ³Department of Preventive Medicine, University of São Paulo Medical School, Brazil.

Human papillomavirus is one of the most common sexually transmitted diseases worldwide. The natural history of oral HPV infection is unclear, and its risk factors have not been explored. Immunocompromised individuals, as exemplified by HIV patients, are at high risk for HPV-related diseases. The mean of this study is to determine the prevalence of HPV in the oral tract of HIV-1-positive male subjects and its association with risk factors. A total of 283 oral wash samples from HIV-1-positive men were tested. The oral fluid samples were used for DNA extraction and conventional PCR amplification; HPV genotyping was performed by hybridization. HPV genotyping revealed that nine samples (3.5%) were positive for HPV DNA; the major high-risk HPV types identified were 51 and 66. Worldwide studies have shown a variable prevalence of oral HPV. The diversity of genotypes and the high prevalence of multiple infections in HIV-infected subjects can be better explained by the effects of HIV-induced immunosuppression. The most important risk factors are unprotected sexual intercourse, but other factors for this infection have been described elsewhere including smoking, age and HIV-positive serostatus. In this study, smoking was the most important risk factor for acquiring oral HPV in HIV-1-infected subjects in Brazil.

Taxonomy. Human papillomavirus (HPV) is one of the most common agents of sexually transmitted diseases worldwide¹. More than 180 HPV genotypes have been classified into different subgroups, with 40 types identified in the genital mucosa^{2,3}.

Human papillomavirus infection. The natural history of genital HPV infection in men is difficult to evaluate because it depends on the anatomical site, sample, sampling methods and HPV DNA detection assays⁴. The highest prevalence of HPV infection in males is found in anogenital sites and in men who have sex with men (MSM). The presence of HPV infection has also been associated with the acquisition of HIV infection⁴.

Oral HPV infection. The oral HPV infection has not been explored^{5–8}. The prevalence of oral HPV varies from 0 to 70% in normal oral mucosa, ranges from 0 to 85% in potentially malignant oral disorders and ranges from 0 to 100% in oral malignancies. This variability is attributed to discrepancies such as sampling variation and limitations of the molecular techniques used in different studies⁹.

Risk factors and HPV. Exposure is determined by risk factors common to most sexually transmitted infections¹⁰. Little is known about the factors contributing to oral HPV infection. Several studies have shown that the number of life-time sexual partners, frequency of sex, oral sex or other intimate skin-to-skin contact increase the chance of being infected by HPV^{10,11}. Additionally, other risk factors have been reported to affect disease development related to HPV infection, including smoking, alcohol use and immunodeficiency^{12–14}.

Immunodeficiency and HPV infection. HIV infection increases susceptibility to opportunistic infections caused by viruses^{15,16}. Thus, several studies have found an increased prevalence of HPV in individuals who are also HIV-infected¹⁷. Likewise, HIV infection can influence the natural history of HPV, by increasing the likelihood of a persistent infection and achieving greater virulence¹⁵.

To date, limited information is available regarding the natural history of oral HPV infection and which risk factors are associated with it. Similarly, little is known about the association between HPV and HIV infections in men¹⁸. The aim of this study was to measure the prevalence of HPV in the oral tract of HIV-1-seropositive men and to evaluate major risk factors for transmission.

Methods

Study population. Two-hundred and eighty-three HIV-1-seropositive male patients referred to the HIV-Out Clinic ADEE3002, Dermatology Department of Hospital das Clínicas, University of São Paulo medical school - HC-FMUSP and the Institute of Infectious Diseases “Emilio Ribas” from December 2011 to May 2013 were included in the study. All patients appeared to have healthy oral mucosa. The mean age was 43.81 years (22–72 years). After signing an informed consent form, patients answered a questionnaire containing information on their social-behavioral characteristics. The study was approved by the respective ethical boards from the Institute of Tropical Medicine of São Paulo and the from Hospital das Clínicas of FMUSP.

Sample collection. Oral washes were performed as follows. Patients were instructed to perform oral rinse with 10 ml of sterile saline solution (0.9% sodium chloride – Baxter International), and the rinses were submitted to sample collection. After collection, samples went through a process of washing and centrifugation. They were then aliquoted and stored at -20°C for later analysis.

Precautions for contamination prevention. Strict procedures were followed to avoid false-positive reactions due to contamination. DNA extraction, reagent preparation and addition of sample DNA were carried out separately. Each area has its own dedicated equipment and every test included a negative control amplification containing distilled water without a DNA sample. All working surfaces were decontaminated with sodium hypochlorite and alcohol (70%), before and after use.

Laboratory methods. Samples were subjected to a DNA extraction process using a commercially available kit (Illustra Tissue and Cells GenomicPrep Mini Spin kit, Easton Turnpike, Fairfield, USA) and, run according to the manufacturer's instructions. After this procedure, the DNA was stored at -80°C for later analysis.

Beta-globin PCR was performed for all samples as a control for DNA quality. The protocol used was previously standardized in the laboratory where the research was conducted. PCR was performed in a final reaction volume of 50 μl , containing 5 μl of template DNA, 10 $\times$ PCR buffer, 50 mM of MgCl_2 , 10 mM of dNTPs, 5 U/ml of Taq DNA polymerase and 10 pmol of each primer. The PCR

conditions were as follows: pre-heated at 95°C for 4 minutes followed by 35 cycles of 1 minute at 94°C , 1 minute at 55°C and 1 minute at 72°C , with a final extension of 7 minutes at 72°C .

HPV detection was carried out with a conventional PCR using the primers MY09/11. The protocol used was previously standardized in the laboratory where the research was conducted. PCR was performed in a final reaction volume of 50 μl , containing 5 μl of template DNA, 0.05 U/ μl of Taq DNA polymerase, 4 mM of MgCl_2 , 0.4 mM of each dNTP, of PCR Mastermix (Thermo Scientific/Waltham - MA) and a final concentration 4 pmol of the MY09/11 primers. The PCR conditions were as follows: preheated at 95°C for four minutes followed by 40 cycles of 1 minute at 94°C , 1 minute at 55°C and 1 minute at 72°C , with a final extension of 7 minutes at 72°C . The presence of HPV DNA was confirmed using electrophoresis on a 2% agarose gel containing ethidium bromide.

Finally, a commercially available kit was used for HPV genotyping (PapillomaStrip High + Low Risk – Operon Immune & molecular diagnostics – Cuarte de Huerva/Zaragoza – Spain). PapillomaStrip is a test based on the reverse blot technique that allows the genotyping of DNA samples and is capable of detecting 18 human papillomavirus subtypes of low-risk (subtypes 6, 11, 40, 42, 43, 44, 54, 61, 62, 67, 70, 71, 72, 74, 81, 83, 84 and 91) and 19 human papillomavirus subtypes of medium-high risk (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 69, 73 and 82). The methods were carried out in accordance with the approved guidelines.

Statistical data analysis. Descriptive statistics were performed with the statistics program SPSS 20.0 and displayed in tables showing frequencies and percentages. The bivariate analysis was performed with the epidemiological statistics of open code for public health – OpenEpi 3.01 software with oral HPV as the dependent variable and age, smoking and alcohol use status, use of condom in sexual relations, practice of oral sex, HIV viral load, CD4 count, and use of HAART, as independent variables. Variables attaining a p value lower than 0.05 on the bivariate analysis were entered in a multivariate logistic model in a forward stepwise fashion. The multivariate analysis was performed with the aid of Stata 12.0 statistical software (StataCorp. 4905 Lakeway Drive, College Station, TX).

Results

Laboratory data and behavioral characteristics of all 283 patients were analyzed. All patients in this study were male and HIV-infected (data not shown), 83% were using HAART, 82.3% had T CD4 cell counts ≥ 350 cell/ mm^3 and 78.8% had undetected HIV viral loads (less than 50 copies).

Table 1 | Distribution of risk factors relative to social habits and laboratory data among 273 HIV-1 positive patients according to their HPV status. Bivariate analysis performed with the OpenEpi statistic program (version 3.01) using the exact test

	*NA	HIV-infected subjects (n = 283) HPV negative (n = 273) (%)	*HPV positive (n = 10) (%)	*p Value
<u>HIV Viral load > 50 copies/ml</u>				
Yes		58(21.2)	2(20)	0.641
No		215(78.7)	8(80)	
<u>T CD4 cells count < 350</u>				
Yes		48(17.6)	2(20)	0.553
No		224(82.4)	8(80)	
<u>HAART use</u>				
Yes		228(83.5)	7(70)	0.230
No		45(16.5)	3(30)	
<u>Alcohol Intake</u>				
Yes		149(54.6)	6(60)	0.498
No		124(45.4)	4(40)	
<u>Cigarette Smoking</u>				
Yes		78(28.6)	8(80)	0.001
No		195(71.4)	2(20)	
<u>Discharge from genital site</u>				
Yes		66(24.2)	3(30)	0.456
No		207(75.8)	7(70)	
<u>Wart from genital site</u>				
Yes		55(20.1)	1(10)	0.378
No		218(79.8)	9(90)	
<u>Wounds from genital site</u>				
Yes		46(16.8)	2(20)	0.529
No		227(83.1)	8(80)	

*NA: no answer.

*p value < 0.05 and confidential limits excluded. Null values (0.1 or [n]) are highlighted.

*HPV positive: the results of oral HPV genotyping were compared with genotypes that infect the anogenital site.

Table 2 | HPV types* from 9 HPV positive patients

Sample ID	HPV High-Risk type	HPV Low-Risk type
01	66	62
02	16,66	06
03	51	—
04	56	44,83
05	51,66	72
06	58	—
07	51,58,66	84
08	51	06
09	66	—
10	58,66,69	67,83

*Types identified through PapillomaStrip high and low risk (Zaragoza, Spain).

Most of the patients had a college degree (45.2%), were single (53.4%), of white ethnicity (60.8%) and did not use drugs (62.5%). We also evaluated alcohol intake and tobacco use: 54.8% ingested some alcohol and 30.4% were current smokers, 3.9% of the patients had smoked for months and 26.5% had smoked for years.

In regards to sexual exposure, 41% reported having had sex with men in the last year, 73.9% reported using a condom with a casual partner and 53.4% reported having engaged in active oral sex. Furthermore, 54.3% had passive oral sex and 52.6% had active anal sex. Approximately 75.4% had no discharge, and 80.2% had no warts or wounds on the genital site.

HPV DNA was found in ten of the 283 samples (3.5%) (data not shown). The mean age of the HPV+ group was 42 years (26–56 years), 70% were using HAART, 80% had T CD4 cell counts ≥ 350 cells/mm³ and undetectable HIV viral loads. Most of the patients were single (80%), 50% had a college degree, most were of white

ethnicity and did use drugs. Among these patients, 80% are smokers and 60% smoke more once a day (Table 1).

For sexual exposure, all of the HPV-positive patients reported having sex with men in the last year, with active anal sex and using a condom with casual partners, 80% had active oral sex, 40% had passive oral sex, 80% had no discharge or wounds and 90% had no warts at the genital site.

HPV DNA was genotyped, identify and classify the subtypes in each sample (table 2). In the high-risk group, the most highly prevalent type was HPV-66 (60%) followed HPV-51 (40%). The HPV-58 type was found in three samples (30%) and the HPV-16, 56 and 69 types were each found once in different samples.

In the low-risk group, the HPV-6 and 83 types were found in two samples (20%) and the HPV-44, 62, 67, 72 and 84 types were each found once in different samples. Three samples had multiple high-risk subtypes, and two samples had multiple low-risk subtype.

Variables such as sexual exposure, alcohol consumption, cigarette smoking, HIV serostatus, HIV viral load, CD4 cell count and HAART use were assessed as possible risk factors for oral HPV (table 3). The bivariate analysis was performed comparing the distribution of factors between HIV-infected men HPV-HIV coinfecting men.

The variables that had significant results based on a p value less than 0.05 were included in the multivariate logistic regression analysis to determine which factors are a risk for oral HPV infection (table 4). The only factor significantly associated the detection of HPV DNA was smoking [OR (CI) = 10.04 (1.98–50.92), $p < 0.01$].

Discussion

Worldwide studies have shown a variable prevalence of oral HPV in healthy individuals¹⁹. This variability may be due to factors such as the difference in the local mucosal immunity, saliva flow and immu-

Table 3 | Distribution of risk factors relative to sexual intercourse among 273 HIV-1 positive according to their HPV status. Bivariate analysis performed with the OpenEpi statistic program (version 3.01) using the Fisher exact test

	*NA (%)	HIV (n = 283) HPV negative (n = 273) (%)	*HPV positive (n = 10) (%)	*p Value
<u>Sexual relationship last year</u>	10 (3.7)			
No sexual relationship		42 (15.4)	0 (0)	0.216
With women		94 (34.4)	0 (0)	0.03
With men		106 (38.8)	10 (100)	0.0001
With both, women and men		21 (7.7)	0 (0)	0.417
<u>Condom with casual partner</u>	10 (4.1)			
Yes		199 (72.9)	10 (100)	0.000001
No		64 (23.4)	0 (0)	
<u>Condom with steady partner</u>	15 (5.5)			
Yes		197 (72.2)	4 (40)	0.302
No		77 (31.7)	6 (60)	
<u>Active oral sex</u>				
Yes		143 (52.4)	8 (80)	0.07
No		130 (47.6)	2 (20)	
<u>Passive oral sex</u>				
Yes		158 (57.9)	10 (100)	0.004
No		115 (42.1)	0 (0)	
<u>Active anal sex</u>				
Yes		139 (50.9)	10 (100)	0.001
No		134 (40.1)	0 (0)	
<u>Passive anal sex</u>				
Yes		103 (42.4)	4 (40)	0.563
No		170 (62.3)	6 (60)	

*NA: no answer.

*p value > 0.05 and confidential limits excluded. Null values (0.1 or [n]) are highlighted.

*HPV positive: the results of oral HPV genotyping were compared with genotypes that infect the anogenital site.

Table 4 | Factors associated with oral HPV entered on the multivariate logistic regression analysis using the STATA program

Oral HPV	P	OddsRatio	CI 95%
Alcohol use	0.338	0.99	0.94 1.03
Smoking	0.01	10.04	1.98 50.92
Condom with casual partner	0.324	1.15	1.05 1.26
Sex relation with men	0.22	0.91	0.86 0.96
Passive Oral sex	0.331	0.94	0.90 0.97

noglobulins in the oral cavity, different methods of sample collection and analysis and propensity to micro trauma injuries^{20,21}.

In HIV-infected subjects, oral HPV infection is more aggressive and more highly prevalent compared with a healthy population^{16,19,22}. A comparative study including HIV-infected patients and healthy subjects found that 25.3% of HIV patients had an HPV infection in the oral tract compared with 7.6% of healthy subjects²³. In the United States, a study was conducted with 190 HIV-positive men, and found that 6.3% them had detectable HPV in their oral fluid samples²³. On the other hand, a study conducted in the United States and Spain with 166 patients showed a prevalence of 21% of oral HPV in HIV-positive MSM individuals, of which 11.1% were low-risk types and 66.6% were high-risk types²⁴. In our study, oral HPV infection was detected in 3.5% of HIV-positive patients, in accordance with both previous results and with the variability found in the prevalence of oral HPV in several studies⁹.

The diversity of genotypes and the high prevalence of multiple infections in HIV-positive subjects can be better explained by the effects of HIV-induced immunosuppression²⁵. Our results demonstrate that most HPV-infected patients had more than one high-risk type.

When comparing the anogenital and oral genotypes, some types could be found at both sites. Regarding the low-risk groups, HPV-6 and 11 are the most prevalent²⁶. In our study, HPV-6 was found in 20% of the samples. In the high-risk group, HPV-16 and 18 were the most prevalent at the anogenital site followed by HPV-31, 33, 39, 45, 51, 52, 53, 58, 59, 66 and 73²⁷. In our study, several high-risk anogenital types were found, especially HPV-66.

The most important classical risk factors are unprotected sexual intercourse and multiple sexual partners²⁰. Several studies have suggested that a high number of lifetime sexual partners, and practices such as kissing, oral-penile sex and hand warts are predictive of oral HPV infection^{20,28}.

Other factors for this infection have been described elsewhere, including smoking and HIV-positive serostatus²⁰. Although some studies indicate that there is conflicting evidence on the relationship between cigarette smoking and HPV infection, several studies suggested that recent cigarette smoking was associated with a significantly increased risk of oral HPV^{29,30}. According to Read and coworkers¹⁴, smoking causes oral epithelial thickening, periodontal disease and epithelial abrasion, thereby increasing the risk of HPV infection.

In this report, we examined the oral tract as a site associated with the presence of HPV infection. After controlling for potential confounding variables, the only risk factor remaining significantly associated with HPV infection in our patients was cigarette smoking ($p < 0.001$).

Studies suggest that HIV-infected individuals may have a higher risk of developing oropharyngeal cancer as well other HPV-associated cancers^{31–33}. Some studies indicate that highly active therapy (HAART) does not reduce the prevalence of oral HPV and that CD4 cell count increases the incidence, progression and persistence of HPV-induced lesion^{16,34}.

In our study, there was no substantial difference between these factors, because the majority of our patients had undetectable HIV

viral loads and their CD4 cell counts were greater than 350 cells/mm³.

We could not determine whether HPV in the oral cavity of our patients had caused any related disease, such as head and neck squamous cell carcinoma (SCCHN) associated with cigarette smoking. However, it is known that these HPV oral carriers are potential transmitters of the virus.

Finally, it is important to acknowledge that most HPV types found in our patients are high-risk types but that, those types are unfortunately not treated by the currently available marketed vaccines. As a highlight, more studies are needed to enable a better understanding of the association between oral HPV infection and its risk factors in HIV-positive people.

1. Reis, A. A. S. *et al.* Infecção viral e os estudos moleculares dos carcinomas associados ao papilomavírus humano. *News Lab.* **92**, 100–108 (2009).
2. Zur Hausen, H. Papillomaviruses in the causation of human cancers—a brief historical account. *Virology* **384**, 260–265 (2009).
3. Muñoz, N. Epidemiological classification of human papillomavirus types associates with cervical cancer. *New Engl J Med.* **348**, 518–527 (2003).
4. Esquenazi, D. *et al.* The frequency of human papillomavirus findings in normal oral mucosa of healthy people by PCR. *Braz J Otorhinolaryngol.* **76**, 78–84 (2010).
5. Seifi, S. *et al.* Prevalence of Oral Human Papilloma Virus in Healthy Individuals in East Azerbaijan Province of Iran. *Iranian J Publ Health.* **42**, 79–85 (2013).
6. Nureña, C. R. *et al.* HPV and genital warts among Peruvian men who have sex with men and transgenders people: knowledge, attitudes and treatment experiences. *Plos One.* **8**, e58684 (2013).
7. Videla, S. *et al.* Natural history of Human Papillomavirus Infections involving anal, penile, and oral sites among HIV-infected men. *Sex Transm Dis.* **40**, 3–10 (2013).
8. Franceschi, S. *et al.* Human Papillomavirus and cancers of the upper aerodigestive tract: a review of epidemiological and experimental evidence. *Cancer Epidemiol Biomarkers Prev.* **5**, 567–575 (1996).
9. Feller, L. *et al.* Epithelial maturation and molecular biology of oral HPV. *Infect Agents and Cancer.* **4**, 01–09 (2009).
10. Alves, D. B. *et al.* Linfócitos CD4, CD8 e células NK no estroma da cérvix uterina de mulheres infectadas pelo papilomavírus humano. *Ver Soc Bras Med Trop.* **43**, 425–429 (2010).
11. Stanley, M. HPV – Immune Response to Infection and Vaccination. *Infect Agents and Cancer.* **5**, 1–6 (2010).
12. Gonçalves, M. A. *et al.* Immune cellular response to HPV: Current concepts. *BJID.* **8**, 1–9 (2004).
13. Ciarra, G. *et al.* Critical Role of the Rb Family in Myoblast survival a fusion. *Plos One.* **6**, e17682 (2011).
14. Smith McCune, K. K. *et al.* Type-Specific Cervico- vaginal Human Papillomavirus Infection Increases Risk of HIV Acquisition Independent of other sexually transmitted Infection. *Plos One.* **5**, e10094 (2010).
15. Kreuter, A. *et al.* Human papillomavirus-associated induction of human beta-defensins in anal intraepithelial neoplasia. *Br J Dermatol.* **160**, 1197–1205 (2009).
16. Low, A. J. *et al.* Genital warts infection with human immunodeficiency virus in high-risk women in Burkina Faso: a longitudinal study. *BMC Infect Dis.* **11**, 20 (2011).
17. Figliuolo, G. *et al.* Clinical and laboratorial study of HPV infection in men infected with HIV. *Int Braz J Virol.* **38**, 411–8 (2012).
18. Baay, M. *et al.* HPV in cervix and vagina. *Sex Transm Infect.* **80**, 249–250 (2004).
19. Amorntharee, K. *et al.* Impacts of HIV infection and long-term use of antiretroviral therapy and the prevalence of oral human papillomavirus type 16. *J Oral Pathol Med.* **41**, 309–314 (2012).
20. Read, T. R. H. *et al.* Oral Human Papillomavirus in men having sex with men: Risk-factors and sampling. *Plos One.* **7**, e49324 (2012).
21. Hagensee, M. E. *et al.* Human papillomavirus infection and disease in HIV-infected individuals. *Am J Med Sci.* **328**, 57–63 (2004).
22. Stuardo, V. *et al.* Human Papillomavirus Infection in HIV-1 infected women in Catalonia (Spain): Implications for prevention of cervical cancer. *Plos One.* **7**, e47755 (2012).
23. Vargas, L. O. S. *et al.* Detection of Human papillomavirus (HPV) in oral mucosa of women with cervical lesions and their relation to oral sex practices. *Infect Agents Cancer.* **5**, 25 (2010).
24. McLemore, M. S. *et al.* Head and neck squamous cell carcinoma in HIV-positive patients: a preliminary investigation of viral associations. *Head and Neck Pathol.* **4**, 97–105 (2010).
25. Hansson, B. G. *et al.* Strong Association between infection with Human Papillomavirus and oral and oropharyngeal squamous cell carcinoma: A population-based case-control study in Southern Sweden. *Acta Otolaryngol.* **125**, 1334–1337 (2005).
26. Danielewski, J. A. *et al.* Human Papillomavirus type 6 and 11 genetic variants found in 71 oral and anogenital epithelial sample from Australia. *Plos One.* **8**, e63892 (2013).

27. Darnel, A. D. *et al.* Correlation between the presence of High-risk human papillomaviruses and ID gene expression in Syrian women with cervical cancer. *Clin Microbiol Infect.* **16**, 262–266 (2010).
28. Schwartz, S. M. *et al.* Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. *J Natl Cancer Inst.* **90**, 1626–1636 (1998).
29. Rangin, C. *et al.* Oral HPV Infection and sexuality: A cross-sectional study in woman. *Int J Mol Sci.* **12**, 3928–3940 (2011).
30. Herrero, R. *et al.* IARC Multicenter Oral Cancer Study Group. Human Papillomavirus and oral cancer: International Agency of Research on Cancer Multicenter study. *J Natl Cancer Inst.* **95**, 1772–1783 (2003).
31. IARC. International Agency for Research on Cancer. Human Papillomaviruses. *Monogr Eval Carcinog Risk Human.* **90**, 1–670 (2007).
32. De Pyeon, S. M. *et al.* Establishment of human papillomavirus infection requires cell cycle progression. *Plos Pathogens.* **5**, e1000318 (2009).
33. Dunne, E. F. *et al.* Prevalence of HPV infection among men: a systematic review of the literature. *J Infect Dis.* **194**, 1044–1057 (2006).
34. Anic, G. M. *et al.* Genital HPV infection and related lesions in men. *Prev Med.* **53**, 536–541 (2011).

Acknowledgments

Fapesp 2010/07076-4; 2011/16094-9. We thank Dr. Jose Vidal and Dr. Margareth Eira for patient referrals from the Emilio Ribas Institute and Dr. Ana Paula R. Veiga, Lucas

Medeiros, Mauricio Ferreira, Arthur Paiva for patients from ADEE/HCFMUSP. We also thank Eduardo Martins and Noemia Orii for technical support.

Author contributions

K.G., L.A.F.M. and J.C. wrote the main manuscript text; O.L., L.A.F.M. and K.G. performed the statistical analysis; T.A., F.C. and A.S.F. prepared tables 1–4, and A.J.S.D. helped with the discussion. All authors reviewed the manuscript and approved the final version.

Additional information

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Gaester, K. *et al.* Human papillomavirus infection in oral fluids of HIV-1-positive men: prevalence and risk factors. *Sci. Rep.* **4**, 6592; DOI:10.1038/srep06592 (2014).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>